Search results
Showing 781 to 795 of 1070 results for drug therapy
Brolucizumab for treating wet age-related macular degeneration (TA672)
Evidence-based recommendations on brolucizumab (Beovu) for treating wet age-related macular degeneration in adults.
Evidence-based recommendations on apalutamide with androgen deprivation therapy for treating hormone-sensitive metastatic prostate cancer in adults.
Evidence-based recommendations on elacestrant (Korserdu) for treating oestrogen receptor-positive HER2-negative advanced breast cancer with an ESR1 mutation after endocrine treatment in adults.
Evidence-based recommendations on trastuzumab deruxtecan (Enhertu) for treating HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 treatments in adults.
Evidence-based recommendations on osimertinib (Tagrisso) for treating EGFR mutation-positive unresectable locally advanced non-small-cell lung cancer after platinum-based chemoradiotherapy in adults.
Evidence-based recommendations on galcanezumab (Emgality) for preventing migraine in adults.
NICE has developed a medtech innovation briefing (MIB) on the Epidrum for aiding access to the epidural space
Non-rigid stabilisation techniques for the treatment of low back pain (HTG239)
Evidence-based recommendations on non-rigid stabilisation techniques for the treatment of low back pain. This involves joining the problem bones together using a non-rigid implant between 2 or more vertebrae.
View recommendations for HTG239Show all sections
Sections for HTG239
Evidence-based recommendations on durvalumab (Imfinzi) with gemcitabine and cisplatin for treating locally advanced, unresectable, or metastatic biliary tract cancer in adults.
Emergency and acute medical care in over 16s: service delivery and organisation (NG94)
This guideline covers organising and delivering emergency and acute medical care for people aged over 16 in the community and in hospital. It aims to reduce the need for hospital admissions by giving advanced training to paramedics and providing community alternatives to hospital care. It also promotes good-quality care in hospital and joint working between health and social services.
Evidence-based recommendations on osimertinib (Tagrisso) with pemetrexed and platinum-based chemotherapy for untreated EGFR mutation-positive advanced non-small-cell lung cancer in adults.
Evidence-based recommendations on pembrolizumab (Keytruda) for neoadjuvant and adjuvant treatment of triple-negative early or locally advanced breast cancer in adults.
Evidence-based recommendations on olaparib (Lynparza) with bevacizumab (Avastin) for high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer in adults.
Evidence-based recommendations on nivolumab (Opdivo) as a possible treatment for completely resected oesophageal or gastro-oesophageal junction cancer in adults.
Aflibercept for treating choroidal neovascularisation (TA486)
Evidence-based recommendations on aflibercept (Eylea) for treating choroidal neovascularisation in adults.